SRTA Form 4: 11,844 Fully Vested RSUs Granted to Director

Rhea-AI Filing Summary

Andrew Lauck, a director of Strata Critical Medical, Inc. (ticker: SRTA), was granted 11,844 fully vested Restricted Stock Units (RSUs) on 08/29/2025. The filing states these RSUs will be settled in shares of the issuer's common stock and are effective upon completion of the issuer's previously announced sale of its Passenger business to Joby Aero, Inc., under the Equity Purchase Agreement dated August 1, 2025. Following this transaction, the reporting person beneficially owns 130,642 shares of Class A common stock. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/03/2025.

Positive

• Grant is fully vested and therefore converts to shares without additional vesting conditions beyond the specified transaction condition
• Transaction is clearly linked to a named sale (Equity Purchase Agreement with Joby Aero dated August 1, 2025), providing explicit settlement trigger
• Post-transaction beneficial ownership is disclosed (130,642 shares), supporting transparency for Section 16 reporting

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Director received fully vested RSUs tied to a specific divestiture; ownership and timing are clearly disclosed.

The Form 4 discloses a grant of 11,844 fully vested RSUs to a director, explicitly tied to the closing of a divestiture (sale of the Passenger business to Joby Aero). The filing identifies the governing contract (Equity Purchase Agreement dated August 1, 2025) as the trigger for settlement in common stock and reports post-transaction beneficial ownership of 130,642 shares. Documentation appears complete for Section 16 reporting: transaction date, nature of award, vesting condition, and resulting ownership are provided. No indications of amendments, option exercises, or derivative holdings are present in this filing.

Securities Analyst

TL;DR: Transaction is a compensation-related equity grant; impact on share count and financials is not quantified in this filing.

The Form 4 shows a grant coded as an acquisition (A) of 11,844 RSUs with a $0 price, described as fully vested and to be settled in common stock upon completion of a specified sale. The filing reports total beneficial ownership after the grant. The document does not provide details on the issuer's outstanding share count, dilution effects, accounting expense, or cash considerations, so material financial impact cannot be assessed from this Form 4 alone.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LAUCK ANDREW

(Last) (First) (Middle)

31 HUDSON YARDS, 14TH FLOOR

C/O STRATA CRITICAL MEDICAL, INC.

(Street)

NEW YORK NY 10001

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Strata Critical Medical, Inc. [ SRTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A common stock, $0.0001 par value per share	08/29/2025		A		11,844(1)	A	$0	130,642	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of fully vested Restricted Stock Units ("RSUs") effective upon the completion of the Issuer's previously announced sale of its Passenger business to Joby Aero, Inc. pursuant to that certain Equity Purchase Agreement, dated as of August 1, 2025. The RSUs will be settled in shares of the Issuer's common stock.

Remarks:

	/s/ Melissa M. Tomkiel, as attorney-in-fact for Andrew C. Lauck	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction is reported on this Form 4 for Strata Critical Medical (SRTA)?

The Form 4 reports a grant of 11,844 fully vested RSUs to director Andrew Lauck, dated 08/29/2025.

When will the RSUs be settled into common stock?

The RSUs are effective and will be settled in common stock upon completion of the sale of the issuer's Passenger business to Joby Aero, per the Equity Purchase Agreement dated August 1, 2025.

How many shares does the reporting person own after the reported transaction?

Following the reported transaction, the reporting person beneficially owns 130,642 shares of Class A common stock.

What is the reported price for the RSU grant?

The Form 4 lists the RSU grant with a reported price of $0 (common for equity compensation awards reported as acquisitions).

Who signed the Form 4?

The Form 4 was signed by Melissa M. Tomkiel, as attorney-in-fact for Andrew C. Lauck, dated 09/03/2025.